Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
about
Optimal management of breast cancer in the elderly patient: current perspectivesBrain sex matters: estrogen in cognition and Alzheimer's diseaseStatus of adjuvant endocrine therapy for breast cancer.The effects of tamoxifen on learning, memory and brain tissues oxidative damage in ovariectomized and naïve female ratsCognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.Do aromatase inhibitors have adverse effects on cognitive function?Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adultsInterpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Cognitive changes associated with endocrine therapy for breast cancer.Clinical utility of exemestane in the treatment of breast cancerSubjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.Why, After Chemotherapy, is it Necessary to Assess Memory Using Translational Testing?Effect of endocrine therapy on quality of life and cognitive functions in patients with breast cancer.Adjuvant ovarian function suppression and cognitive function in women with breast cancer.Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer.Cognitive dysfunction in postmenopausal breast cancer patients on aromatase inhibitors.Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives.Safety of aromatase inhibitor therapy in breast cancer.Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review.Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.An update on adjuvant systemic therapy for elderly patients with early breast cancer.Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature.Memory and Spatial Cognition in Breast Cancer Patients Undergoing Adjuvant Endocrine TherapyInhibition of oestrogen biosynthesis induces mild anxiety in C57BL/6J ovariectomized female mice.Systemically treated breast cancer patients and controls: an evaluation of the presence of noncredible performance.Convergent and criterion validity of the CogState computerized brief battery cognitive assessment in women with and without breast cancer.A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery.Assay of Calcium Transients and Synapses in Rat Hippocampal Neurons by Kinetic Image Cytometry and High-Content Analysis: An In Vitro Model System for Postchemotherapy Cognitive Impairment.
P2860
Q27690879-B7820AAD-1F4B-4D9A-97F3-1E3AB89AB705Q33693268-9A872561-A289-4EA6-AA93-32B1436A2CFFQ33739138-CEB73C23-EF0A-404A-A90D-1A8DD12B6B75Q34447790-ADC83161-DF53-4E92-8C36-545A0A0BBF13Q34604179-C8E9FAA5-B0C5-40E8-8A58-E7ED49A86FDEQ35029513-AC5E6640-76A3-4151-9B80-F2835B24FCECQ35164117-A1B99367-6102-43FF-B698-3C7431F0A929Q35557992-7C6FBF34-2CA0-42AC-8E77-574B39367D49Q35660927-39547B88-F6E0-47EC-9F2D-A3EB6700FA4BQ35683807-37A51744-D447-46A4-B4BD-C8FAA63198CBQ35949546-98561BB7-B1DC-4366-A2CF-4D36370BF193Q36440620-D165A2C5-C162-49E1-BE6F-F7854EE0F44AQ36932994-4ADDA569-EDC6-472A-AAB0-5F8289BCA951Q37175081-9DD3242E-049F-49E4-95FC-B8CE0912A798Q37314706-E0D18E5B-BE48-4606-940E-38C370283AFBQ37931900-B98D213B-5D16-437E-AEE4-484E0699BA6EQ37976412-CADF8F06-BA2A-4837-9227-DAC50FDEC127Q38522924-60037815-DA26-415C-A58D-F34860DCD62FQ38551397-9A0C72A1-3755-4903-A29C-DDE0E69463BEQ38594867-AC0B3EF4-0450-4BF6-B79F-392745B2625DQ38786134-EA4E4A79-E271-4AEE-8FBB-5965E4DBF43FQ38931502-6DD29C30-B750-4917-998B-F7BC80711C9DQ39212333-D096E088-4A3E-485B-AAB0-09903229A0F8Q41212362-BE12D447-EB24-471D-BC8A-7D5980DCCCBFQ41442004-0A13336F-7306-420F-8C91-7A5A8137E33CQ44167887-F36DBDAD-B4E2-462E-BA4B-53385483A5EFQ47590961-8A029C13-65C3-4315-BA64-8BBBCBB0D032Q48014012-86F70A86-8055-43C4-86C0-4F93046FEE29Q48647594-EB2F04A7-1CC2-4A69-841E-FDC2BCF284C1Q50882231-D244E0CF-CB63-440C-AB49-E83702213F6C
P2860
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@ast
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@en
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@nl
type
label
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@ast
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@en
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@nl
prefLabel
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@ast
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@en
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@nl
P2093
P2860
P1433
P1476
Cognitive function in postmeno ...... the BIG 1-98 randomized trial.
@en
P2093
Alan S Coates
Alastair Thompson
Alisa Stephens
Aron Goldhirsch
Beat Thürlimann
Fatima Cardoso
Jürg Bernhard
Karen N Price
Karin Ribi
Kelly-Anne Phillips
P2860
P304
P356
10.1016/J.BREAST.2010.03.025
P577
2010-04-10T00:00:00Z